马达加斯加塔那那利佛5岁以下儿童单价轮状病毒疫苗效果及2010-2022年长期影响
在马达加斯加塔那那利佛两家医院,采用检测阴性病例对照设计评估6-23月龄儿童接种单价轮状病毒疫苗对实验室确诊轮状病毒住院的保护效果,并分析2010-2022年疫苗引入前后急性水样腹泻住院占比和轮状病毒阳性率变化。至少一剂疫苗调整后VE为61%(95%CI:-39%-89%)。腹泻住院占比中位数从疫苗前28%降至疫苗后10%,轮状病毒阳性率从59%降至23%。
要点
- 6-23月龄儿童至少一剂单价轮状病毒疫苗对轮状病毒腹泻住院的调整VE为61%(95%CI:-39%-89%)。
- 腹泻住院占比中位数从疫苗前28%降至疫苗后10%。
- 住院急性水样腹泻患儿轮状病毒阳性率疫苗前59%、疫苗后23%。
核心结论
- 轮状病毒疫苗已在马达加斯加常规儿童免疫规划中成功实施,对轮状病毒疾病负担产生很大影响,支持继续使用轮状病毒疫苗。
研究设计与样本
- 采用检测阴性病例对照设计,纳入2010-2022年塔那那利佛两家医院6-23月龄有明确接种记录的儿童,估计单价轮状病毒疫苗对实验室确诊轮状病毒住院的效果。
- 影响评估扩展至0-59月龄急性水样腹泻儿童,使用入院登记数据比较疫苗前(2010年1月-2013年12月)、过渡期(2014年1月-2014年12月)和疫苗后(2015年1月-2022年12月)腹泻住院占比。
- 使用主动监测数据(2013年6月-2022年5月)按疫苗引入时期和监测年度(6月1日-次年5月31日)描述轮状病毒阳性率和基因型。
主要发现
- 6-23月龄儿童至少一剂疫苗对轮状病毒腹泻住院的调整VE为61%(95%CI:-39%-89%)。
- 腹泻住院占比年度中位数从疫苗前28%降至疫苗后10%。
- 0-59月龄住院急性水样腹泻儿童轮状病毒阳性率疫苗前为59%,疫苗后为23%。
- 疫苗前优势基因型为G3P[8](76%)和G2P[4](12%)。
- 疫苗后G1P[8]和G2P[4]占检出基因型的50%以上,基因型随监测年度变化。
临床怎么用
- 作者结论支持在马达加斯加继续使用轮状病毒疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Monovalent rotavirus vaccine substantially reduced rotavirus disease burden after introduction (May 2014) in Madagascar. We examined the effectiveness and long-term impact on acute watery diarrhea and rotavirus-related hospitalizations among children <5 years old at two hospitals in Antananarivo, Madagascar (2010-2022). METHODS: We used a test-negative case-control design to estimate monovalent rotavirus vaccine effectiveness (VE) against laboratory-confirmed rotavirus hospitalizations among children age 6-23 months with documented vaccination status adjusted for year of symptom onset, rotavirus season, age group, nutritional status, and clinical severity. To evaluate the impact, we expanded to children age 0-59 months with acute watery diarrhea. First, we used admission logbook data to compare the proportion of all hospitalizations attributed to diarrhea in the pre-vaccine (January 2010-December 2013), transition period (January 2014-December 2014), and post-vaccine (January 2015-December 2022) periods. Second, we used active surveillance data (June 2013-May 2022) to describe rotavirus positivity and detected genotypes by vaccine introduction period and surveillance year (1 June-31 May). RESULT: Adjusted VE of at least one dose against hospitalization due to rotavirus diarrhea among children age 6-23 months was 61 % (95 % CI: -39 %-89 %). The annual median proportion of hospitalizations attributed to diarrhea declined from 28 % in the pre-vaccine to 10 % in the post-vaccine period. Rotavirus positivity among hospitalized children age 0-59 months with acute watery diarrhea was substantially higher during the pre-vaccine (59 %) than the post-vaccine (23 %) period. In the pre-vaccine period, G3P[8] (76 %) and G2P[4] (12 %) were the dominant genotypes detected. Although genotypes varied by surveillance year, G1P[8] and G2P[4] represented >50 % of the genotypes detected post-introduction. CONCLUSIONS: Rotavirus vaccine has been successfully implemented in Madagascar's routine childhood immunization program and had a large impact on rotavirus disease burden, supporting continued use of rotavirus vaccines in Madagascar.
引用
- Raboba JL, Rahajamanana VL, Rakotojoelimaria HE, et al. Monovalent rotavirus vaccine effectiveness and long-term impact among children <5 years old in Antananarivo, Madagascar, 2010-2022. Vaccine. 2024. PMID: 39260057. doi:10.1016/j.vaccine.2024.126321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。